While Mitch Skop, its senior director of product development, freely admits the company is “not Procter & Gamble”, it is launching a major campaign to back the package that includes a sales force of 12 reps and a B2B campaign that will include full-page ads.
“The marketing budget is sizeable,” he said for the campaign backing the clinically-backed ingredients.
Phase 1 hunger controller contains palm oil and galactolipids from oat oil to form flavored beverage powders (Olibra) for which a study published in the International Journal of Obesity showed subjects consuming foods containing Olibra had significantly reduced food intake at subsequent meals.
Another study at Maastricht University, The Netherlands, showed the ingredient to be effective in helping subjects maintain their weight over a longer term of 18 weeks, Pharmachem said.
Phase 2 carb controller is a white bean extract clinically shown to reduce the digestion of starches in more than 20 studies.
Phase 3 sugar controller is an L-arabinose-derived powdered formula shown to be effective in supporting health blood sugar levels. One human study showed that 1.1gm of the material had a significant effect on improving blood sugar and insulin levels after consumption of a beverage containing 70 grams of sugar.
L-arabinose is a new offering for the company.
Skop said the dietary supplements industry was being targeted although Phase 1 and 2 were being utilized by the food and beverage industry, and customers had the opportunity to mix and match the offerings as they saw fit.
He would not reveal pricing details.
The range backed by a 500-page dossier the company had compiled and which it was making available to customers.
In a statement Skop said: “As we continue to thoroughly research obesity trends and eating habits as they affect weight gain and loss, we realized that portion size and sugar consumption are significant contributors to weight gain and poor health.”